中西医结合治疗慢性荨麻疹临床疗效观察及安全性评价

Clinical Observation of Integrative Medicine in Treatment of Chronic Urticaria and Its Safety Evaluation

目的:探讨慢性荨麻疹患者应用中西医结合治疗临床疗效及其安全性评价。方法:本组270例慢性荨麻疹患者根据随机数字表法随机分为对照组和观察组,各135例。对照采用西药治疗,观察组在对照组治疗基础上结合中医药治疗;两组患者均以2周为1个疗程,连续服用两个疗程后对比分析两组患者治疗后临床疗效、血清炎症因子变化及不良反应发生情况。结果:观察组治疗后总有效率(93.34%)显著高于对照组(72.59%),且差异具有统计学意义(P<0.05);观察组治疗后TNF-α、IL-4、Ig-E均显著低于治疗前及对照组治疗后,IL-18高于治疗前及对照组治疗后,且差异均具有统计学意义(P<0.05);观察组复发率(8.46%)显著低于对照组(42.52%),且差异具有统计学差异(P<0.05);两组不良反应发生率比较差异不具有统计学意义(P<0.05)。结论:慢性荨麻疹患者应用中西医结合治疗疗效显著,且无明显不良反应,临床上应用安全可靠,值得进一步推广研究。

Objective： To investigate the clinical efficacy and safety evaluation of combination therapy of TCM and Western medicine in the treatment of chronic urticaria patients. Methods： 270 cases of chronic urticaria patients were randomly divided into control group and observation group based on a random number table,135 cases in each. Control group used the Western medicine and the observation group combined with TCM therapy based on the Western medicine. Two weeks was a course of treatment. After two courses,the comparative analysis of the clinical efficacy of two groups was carried out and the serum inflammatory factors change and adverse events were observed. Results： The total treatment efficiency（ 93. 34%） in the observation group was significantly higher than that（ 72. 59%） of the control group and the difference was statistically significant（ P〈 0. 05）. In the observation group after treatment,TNF- α,IL- 4 and Ig- E were significantly lower than those pre- treatment and post- treatment in the control group and IL- 18 was higher than the that of the control group before treatment and after treatment and the differences were statistically significant（ P〈 0. 05）. The observation group＇s relapse rate（ 8. 46%） was significantly lower than that（ 42. 52%） in the control group and the difference was statistically significant（ P〈 0. 05）. The two groups＇ incidence of adverse reactions had no statistically significant difference（ P〈 0. 05）. Conclusion： Integrative therapy is significant for patients with chronic urticaria and has no significant adverse reactions. Its clinical application is safe and reliable and it is worthy of further promotion of research.